Rheumatology

Article	Citations
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy	152
Validation of a questionnaire for central nervous system aspects of joint pain: the CAP questionnaire	110
Comment on: Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance	96
COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study	78
Comment on: Switching from prednisolone to dexamethasone in difficult-to-treat rheumatoid arthritis	65
Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply	64
Comment on: Increased risk of osteoporosis and femoral neck fractures in patients with familial Mediterranean fever—a large retrospective cohort study	64
Boxer’s shape, an unusual finding in nailfold capillaroscopy	63
Correction to: Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis	58
Editor’s Acknowledgement	58
Clinico–pathological phenotypes of systemic sclerosis–associated myopathy: analysis of a large multicentre cohort	56
A case of carpal tunnel syndrome caused by gouty tophi confirmed by dual-source CT	55
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: reply	52
Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis	52
Soluble BDCA-2 as a potential biomarker for rheumatoid arthritis and its role in enhancing IFN-α production through nucleic acid binding	50
Combined radiographic and US evaluations to decipher joint involvement in the hands of patients with SSc	50
Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective study	49
OA22 Methotrexate drug monitoring and referral patterns to Hepatology - can we improve detection and monitoring of hepatoxicity with methotrexate use?	49
Giant cell arteritis of the prostate	48
Comment on: Predictors of lack of response to methotrexate in juvenile idiopathic arthritis–associated uveitis	48
E44 Differences of hematological abnormalities between COVID-19 infection and multisystemic inflammatory syndrome (MIS-C)	47
P011 Rituximab and COVID-19 vaccines; are they fit for purpose?	45
29 Juvenile idiopathic arthritis and osteogenesis imperfecta: an exceptional association	44
The state of data sharing in rheumatology: a systematic review of top journal practices	44
P042 Using a Genetic PROBability tool (G-PROB) to aid diagnosis of patients with inflammatory arthritis: results from the Norfolk Arthritis Register	44

P114 Medication adherence to b/tsDMARDS remains sub-optimal in refractory rheumatoid arthritis	43
67 Double impact: hypophosphatemic rickets and vitamin D intoxication	43
P131 Adult coeliac disease and bone mineral density at the femoral neck, total hip and lumbar spine: an age- and sex-matched case-control study	42
P173 The positive utility of PSAID-12 score in remote monitoring and the impact of gender and treatment on patient reported outcomes in psoriatic arthritis	42
E046 Lytic lesions; metastatic disease or gout?	42
P073 Functional investigation of Osteoarthritis-associated non-coding variants using CRISPR/Cas9-mediated perturbation of active enhancer regions	41
OA44 Increasing access to rehabilitation for knee and hip osteoarthritis - ESCAPE-pain in leisure/community centres	41
P143 Frailty is associated with inflammation, impaired glucose metabolism and reduced bone mineral density after adjustment for fat mass index: a UK biobank study	41
P083 Undergraduate rheumatology teaching in the UK: a survey of teachers	41
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment	40
P058 Pneumocystis Jirovecii Infection in autoimmune inflammatory rheumatic diseases in Oxford	40
P041 Successful reversal of microvascular damage with standard therapy in a case of dermatomyositis overlap syndrome	39
P033 The intriguing association between fibromyalgia, hypermobility and neurodivergence: a pilot study	39
E051 Audit of the management of patients over 75 with osteoporotic fragility fractures in primary care	39
26 Kawasaki’s disease vs systemic juvenile idiopathic arthritis, a diagnostic dilemma	38
P110 Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit	38
E078 Inflammation modifies the effect of rheumatoid arthritis in overall mortality among females	38
P043 Income-Related Health Inequality and Osteoarthritis Intervention Outcomes: a Cohort Study	38
P077 Developing a better explanation of osteoarthritis: results from a conjoint analysis of patient preferences	36
P004 Empowering the reproductive choices of patients with rheumatic disease: using the BSR 2022 pregnancy guidelines audit tool to evaluate pre-conception medication advice	36
P185 Patients' and clinicians' perspectives on the clinical utility of the Rheumatoid Arthritis Foot Disease Activity Index	35
P179 A feasibility randomised controlled trial of a fibromyalgia self-management programme in a community setting with a nested qualitative study	35
Comment on: Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: a nationwide cross-sectional study among more than 12 000 patients	35
OA04 COVID-19 admissions and mortality in patients with early inflammatory arthritis: results from a national cohort	35
OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years	34
Comment on: Impact of baseline proteinuria level on long-term outcomes in lupus nephritis	34
P004 Temporal and regional variation in the initiation of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study	34
P104 The role of occupational therapy for the self-management of rheumatoid arthritis: a mixed methods systematic review	33
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies	33
54 Kawasaki disease: experience in a general paediatric department of the CHU de Annaba Algeria	33
P133 Experiences of people with digital ulcers through filmed interviews	33
P174 Identifying patterns of fatigue across flares in patients with axial spondyloarthritis	33
Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis–associated interstitial lung disease	32
Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib	32
Enhancing diagnosis of gout with deep learning in dual-energy computed tomography: a retrospective analysis of crystal and artefact differentiation	31
Transient osteoporosis of the hip: a novel vascular manifestation of COVID-19?	31
Impaired humoral and T helper cell responses to toxic shock syndrome toxin-1 (TSST-1) in granulomatosis with polyangiitis	31
Central retinal vein and cilioretinal artery occlusion in a case of systemic sclerosis treated with a JAK inhibitor figlotinib	31
A systematic review of patient-reported outcome measures in patients with anti-neutrophil cytoplasmic antibody associated vasculitis	30
Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib	30
An ultrasound negative for subclinical synovitis in arthralgia patients: is it helpful in identifying those not developing arthritis?	30
Comparative risk of blindness and vision-threatening ocular comorbidities in patients with Behçet’s disease versus the general population	30
Sensorineural hearing loss in anti-interleukin-1 treated CAPS patients: risk factors and real-life barriers—an observational study	30
The usefulness of ultrasound in predicting outcomes in patients with shoulder pain: a prospective observational study	30
Neither ultrasound synovitis nor clinical-ultrasound phenotypes of established rheumatoid arthritis predict response to targeted therapy	30
Bezoar secondary to NSAID use in a patient with inflammatory arthritis	30
Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus	29
IGFBP5 regulates fibrocartilage differentiation and cartilage injury induced by T-2 toxin via blocking IGF-1/IGF-1R signalling	29
The effect of silver fibre gloves on Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial	29
P261 Early and accurate diagnosis of patients with axial spondyloarthritis using machine learning: a predictive analysis from electronic health records in the United Kingdom	28

High levels of EPSTI1 enhance IFN-β-mediated HLA-A expression and chemokine secretion in myoblasts in dermatomyositis	28
Lupus serology: off target but still relevant to the treat-to-target strategy in systemic lupus erythematosus	28
Bullous periorbital oedema in anti-p155/140-positive dermatomyositis: a case series	27
Prodromal symptoms of rheumatoid arthritis in a primary care database: variation by ethnicity and socioeconomic status	27
Clinician views concerning the prevalence and impact of granulomas on the diagnosis, management, and outcomes of ANCA-associated vasculitis	27
Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study	27
Will we ever agree on using low-dose glucocorticoids in treating rheumatoid arthritis?	27
Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study	27
VEXAS syndrome mimicking lupus-like disease	27
Examination of nailfold videocapillaroscopy findings in ANCA-associated vasculitis	27
Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3	27
Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis	26
Type I interferon dysregulation drives distinct pathogenic pathways in early- and late-onset lupus nephritis	26
Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment	26
The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus	26
Oesophageal dysmotility patterns are associated with distinct clinical phenotypes and prognosis in patients with systemic sclerosis	26
A child with CANDLE syndrome presenting as seronegative polyarthritis following early chemotherapy	26
Biopsy vs imaging for the diagnosis of giant cell arteritis. Viewpoint 2: in favour of biopsy	26
Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus	25
The influence of biological DMARDs on aseptic arthroplasty loosening: a retrospective cohort study	25
Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity	25
Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis	25
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis—caution is key in interpreting retrospective data: Reply	25
Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review	25
Human dermal fibroblast-derived exosomes induce macrophage activation in systemic sclerosis	25
Identification and characteristics of patients with axial psoriatic arthritis: clinical, phenotypic and imaging associations	25
Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE	25
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis	25
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE	25
Lymphocyte subset phenotyping for the prediction of progression to inflammatory arthritis in anti-citrullinated-peptide antibody-positive at-risk individuals	25
Anti-nuclear valosin-containing protein-like autoantibody is associated with calcinosis and higher risk of cancer in systemic sclerosis	25
Negative back beliefs are associated with increased odds of low back pain and disability: a 10-year cohort study in men	25
Gastrointestinal manifestations in systemic lupus erythematosus: data from an Indian multi-institutional inception (INSPIRE) cohort	25
Risk of major organ involvement in Behçet’s patients with mucocutaneous onset: data from the AIDA Network Registry	25
Giant thymic cyst overclouding the diagnosis of fibrodysplasia ossificans progressiva: an inconvenient coincidence	24
The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership	24
The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis	24
Correction to: TLR8 aggravates skin inflammation and fibrosis by activating skin fibroblasts in systemic sclerosis	24
Comment on: Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort	24
Osteophytes’ position in subjects with DISH and right-sided aorta: verification of the ‘aortic pulsation protective effect’ theory	24
Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 2: plasma exchange may be useful under some circumstances	24
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	24
Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study	24
Activation of circulating monocytes by low-density lipoprotein—a risk factor for osteoarthritis?	24
Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry)	24
Ex vivo cell-based assay for assessment of response to TNF inhibitors in patients with rheumatic diseases	24
Avacopan may not independently reduce ANCA titres in ANCA-associated vasculitis: a retrospective analysis of 57 patients	24
Advances in the diagnosis of myocarditis in idiopathic inflammatory myopathies: an overview of diagnostic tests	24
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	24
Ixekizumab-associated disseminated tinea corporis in a patient with psoriatic arthritis and plaque psoriasis	24
Comment on: Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports	24
P133 Attitudes to Technology supported Rheumatoid Arthritis care: Opportunities & Barriers for technology in RA - Key themes from Qualitative arm of Mixed-Methods Study	23
E68 Kawasaki Disease before and during COVID-19	23
P046 The influence of deprivation in the outcomes of Psoriatic Arthritis within the UK - utilising Outcomes of Treatment in Psoriatic Arthritis Study Syndicate data	23
P208 PET-CT scanning of GCA patients: the additive role of opportunistic screening for cardiovascular disease in a high-risk population	23
P110 Characteristics of Difficult to treat Rheumatoid Arthritis patients in a large District Hospital in the UK	23
P027 Infliximab in the treatment of cerebral tuberculosis paradoxical reactions with vasculitis	23
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study	23
E71 Distribution of cells and extracellular matrix in the normal marginal synovium of the hip joint capsule during the postnatal period	23
OA01 Cluster medicine: the role of genetics for identifying shared biological pathways between rheumatoid arthritis and common comorbidities for targeting treatments	23
P212 Understandings and responses to joint pain: preliminary findings from a rapid ethnographic assessment in Northern Tanzania	22
P038 The importance of looking carefully for the cause(s)	22
P055 Gabapentinoid use and the risk of fractures in patients with inflammatory arthritis: nested case-control study in the Clinical Practice Research Datalink Aurum	22
Multicentric Castleman disease presenting with frequent urination	22
20 Does hip involvement affect foot and ankle in juvenile idiopathic arthritis?	22
P229 Integrated analysis of dermal blister fluid proteomics and skin biopsy transcriptomics gives new insight into pathogenesis of systemic sclerosis	22
P163 The cytokine horror: Kawasaki disease shock syndrome complicated with macrophage activation syndrome	22
64 Conical teeth? Think outside the box!	22
OA36 Bimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study	22
E005 Investigation into the post-diagnostic care and follow-up of patients with giant cell arteritis post-initiation of long-term glucocorticoids at University Hospitals Leicester NHS Foundation Trust	22
OA28 VEXAS, a service evaluation in Rheumatology at Sheffield: “Seek, and ye shall find”	22
P245 Identifying predictors of short-term response to rituximab in extra-glandular primary Sjogren’s Syndrome	22
OA06 Single-centre experience of the use of Rituximab for inflammatory arthritis during the COVID-19 pandemic	22
P012 Pneumocystis jirovecii pneumonia in rheumatology patients - a single centre ten-year audit	21
E001 Pre-screen chest X-ray before starting methotrexate in autoimmune disease	21
P094 Experts in lived experience: CLUSTER Champions and their successful collaboration in JIA research	21
E005 An audit of demographics, symptoms & investigations: Part of the survey of GCA in the SEHSCT during the COVID-19 pandemic	21
61 The nailfold videocapillaroscopy in pediatric Behçet’s disease: a multi-center study	21
P127 A retrospective cohort study assessing outcomes and safety in patients receiving low dose vs high dose cyclophosphamide in myositis interstitial lung disease	21
P081 Is it necessary to test vitamin D prior to zoledronate or denosumab treatment?	21

P303 Development of a Behçet’s disease specific patient concerns inventory	21
56 Prevalence and severity of infections in patients with systemic autoimmune diseases on biotherapy	21
P247 Novel therapeutic peptides targeting CD206 modulate ATP-induced release of inflammatory and B cell activating factors in lupus macrophages	21
P117 Remote monitoring of rheumatoid arthritis using RAPID3 to support patient-initiated follow up	21
Where are we now in biologic drugs for myositis?	20
The SUMO components in rheumatoid arthritis	20
HLA-C*06–defined endotype in psoriatic disease: an ever-widening landscape	20
Assessing the role of climate and the environment as co-factors for vasculitis diseases	20
Risk of venous thromboembolism in people with RA: a population-based study in the UK	20
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation	20
Correction to: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis	20
Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews	20
Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study	20
Comment on: risk of urinary tract infections associated with SGLT2 inhibitor use in patients with rheumatoid arthritis: a target trial emulation study: reply	19
Correction to: Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study	19
IFN-α levels correlate with muscle disease activity only in juvenile dermatomyositis patients with anti-MDA5+ autoantibodies	19
Erratum to: Parvovirus B19 induces cellular senescence in human dermal fibroblasts: putative role in systemic sclerosis-associated fibrosis	19
Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort	19
Tofacitinib as a possible treatment for arthritis in an APDS2 patient	19
Addressing the unmet needs of transitional care in juvenile idiopathic arthritis	19
Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study	19
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease	19
Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study	19
Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study	19
Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles	19
Neutrophil-to-lymphocyte ratio as a biomarker for disease onset and mortality risk in SSc: a real-world national cohort study	19
Increased risk of myocarditis and arrythmias in anti-Ku-positive scleroderma–myositis overlap patients: a case series	18
77 Case series of juvenile scleroderma from Nigeria	18
A case of hypertrophic pachymeningitis with neutrophil extracellular traps formation	18
Registry based studies on pregnancy and rheumatic diseases: generating actionable evidence	18
Physical activity in relation to the risk of systemic lupus erythematosus: a prospective study including 401 745 individuals	18
Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders	18
Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study	18
Predicting treatment response to methotrexate: are we closer to solving the enigma?	18
Avacopan in an ocular complication of ANCA-PR3 vasculitis without kidney involvement	18
Interstitial lung disease in limited cutaneous systemic sclerosis patients: never let your guard down	18
P278 Baseline characteristics and treatment response to ixekizumab categorised by sex in radiographic and non-radiographic axial spondylarthritis patients through 52 weeks: data from three phase III,	18
Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry	18
When should we start screening for hydroxychloroquine retinopathy?	18
Upadacitinib in the treatment of Takayasu arteritis: a case report on new perspectives on targeted immunomodulation	18
P257 Are there regional variations in access to biological disease modifying anti-rheumatic drugs for the treatment of psoriatic arthritis in England?	17
P301 Patient reported outcome measure for giant cell arteritis: clinical testing	17
E048 A review of published data on reported staffing ratios for rheumatology specialist physiotherapists in rheumatology departments	17
E29 Juvenile Idiopathic Arthritis (JIA) in Algeria, from diagnosis to management	17
P133 Anti-synthetase syndrome: an experience from a tertiary referral center	17
Comment on: Systemic lupus erythematosus patients have unique changes in serum metabolic profiles across age associated with cardiometabolic risk: reply	17
Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthri	17
P156 Type I interferon is raised across connective tissue diseases and is associated with haematological abnormalities and specific autoantibody profiles	17
P177 Investigating the neural differences in individuals with chronic widespread pain or fibromyalgia and the effect of sleep: a cross-sectional study using data from UK Biobank	17
E044 Telephone clinic consultations in the COVID-19 era: the rates of conversion to face-to-face appointments and discharges in the post-pandemic years	17
P106 Feasibility Study of Methotrexate use Improvement in Rheumatoid Arthritis using Biomarker Feedback: The MIRA Trial	17
Quantitative chest imaging and prediction of mortality in rheumatoid arthritis–associated interstitial lung disease	17
P284 Evaluation of a self-management smartphone app for those living with Sjögren’s syndrome: a fully remote randomised pilot and feasibility trial	17
OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications	17
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis	17
P039 Haemophagocytic lymphohistiocytosis secondary to invasive aspergillosis in a patient with undiagnosed SLE	17
P296 Giant cell arteritis/large vessel vasculitis with normal inflammatory markers: a case series of 15 patients in south Manchester	17
P274 The effect of ixekizumab versus adalimumab on individual components of the ACR composite score, with and without concomitant methotrexate or other conventional synthetic DMARDs, at 52 weeks in pa	17
Raynaud’s phenomenon and digital ischaemia induced by ixekizumab	17
Citrate in the management of gout, urate nephrolithiasis and kidney disease: an old therapy rediscovered?	17
P293 Tocilizumab for refractory or relapsing giant cell arteritis: audit data from the Bristol and Bath regional multidisciplinary meetings 2018-2021	17
A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary care	16
P130 Pharmacist-led osteoporosis telephone service	16
P066 Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients	16
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate	16
Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study	16
Teledidactic peer-tutored musculoskeletal ultrasound training for medical students—the TELMUS study	16
Use of primary health care and radiological imaging preceding a diagnosis of rheumatoid arthritis: a nationwide cohort study in Denmark	16
Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment	16
P113 Cellular profiling of synovial fluid in inflammatory arthritis highlights disease-specific cell states with biological and diagnostic relevance	16
P123 Biologic dose tapering: a patient perspective	16
P167 COVID-19 perniosis, a differential diagnosis to consider in adolescent patients presenting with chilblain-like lesions	16
COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis	16
Nailfold videocapillaroscopy findings correlate with lung outcomes in idiopathic inflammatory myopathies–related interstitial lung disease	16
Sarcoid myopathy: an insidious diagnosis that can mimic inclusion body myositis	16
Correction to: Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region	16
Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry	16
History of tonsillectomy is associated with glandular inflammation in Sjögren’s disease	16
Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus–associated refractory cerebral vasculitis induces immune tolerance	16
P139 Impact of hand function impairment on daily life of patients with systemic sclerosis - a qualitative study	16
Highlights from the plenary session: eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome	16
Antibody predictors of mortality and lung function trends in myositis spectrum interstitial lung disease	16
Is the relationship between deprivation and outcomes in rheumatoid arthritis mediated by body mass index? A longitudinal cohort study	16
Fine particulate matter air pollution and anti-nuclear antibodies	16
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis	16
Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study	16
OA38 Prevalence of cardiovascular disease and its risk factors in rare autoimmune rheumatic diseases: results from a large population-based study	15
OA32 A national survey of rheumatology telephone adviceline support in the United Kingdom: frontline perspectives	15
E047 Utilization of complementary and alternative medicine in patients with rheumatological conditions at Kenyatta National Hospital	15
OA40 Longitudinal metabolomic shifts in RA: insights from 49 NMR spectra show changes at 7 years	15
E050 Developing multidisciplinary models of care in rheumatology at University College London Hospital: 18 months of learning from conception to delivery and beyond	15
E34 Coexisting sickle cell disease and autoimmune diseases among Nigerian children	15
E077 Evaluation of group education for patients with large vessel vasculitis prescribed subcutaneous methotrexate	15
E015 A case of ocular myasthenia gravis seen by rheumatology as suspected mononeuritis multiplex in an adult male shortly after Pfizer-BioNTech SARS-CoV-2 vaccination	15
P191 Efficacy and improvement in patient-reported outcomes at weeks 16 and 52 in ixekizumab treated biological naïve patients with radiographic axial spondyloarthritis achieving clinically important p	15